The Path to Transparency

Navigating the 340B Rebate Model Ruling

A recent ruling from the United States District Court for the District of Columbia has brought new momentum and important questions to the future of the 340B rebate model. As the rebate model continues to be a key opportunity for transparency, accountability, and sustainability in drug discount programs, it is essential to understand the ruling's implications and the way forward.


Key Takeaways:
  • The court’s acknowledgement that a rebate model is permissible under the 340B statute
  • The position of HHS on allowable conditions, including the provision of claims data, for covered entities to purchase 340B-priced products
  • The risks associated with the ongoing lack of transparency in the 340B program
  • The role of data and technology in building a sustainable 340B future
  • What manufacturers can do now to stay ahead of evolving policy changes
At Kalderos, we pioneered and continue to advocate for the rebate model, believing that transparency is critical to the 340B program’s success and its ability to serve the patients it was designed to help.

Watch Now

Provide Your Details for Access